ArticleNature communications2018

LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway.

Ang Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.